19 May 2013
Keywords: Novartis, Exelon Patch, Alzheimer's disease, Higher dose, USA, FDA
Article | 04 September 2012
The US Food and Drug Administration has approved a higher dose of Swiss drug major Novartis’ (NOVN: VX) Exelon ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 September 2012
3 September 2012
17 May 2013
© 2013 thepharmaletter.com